Latest Healthcare News

Page 33 of 150
LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.
Ada Torres
Ada Torres
29 Oct 2025
Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.
Ada Torres
Ada Torres
29 Oct 2025
Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.
Ada Torres
Ada Torres
29 Oct 2025
Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.
Ada Torres
Ada Torres
28 Oct 2025
OncoSil Medical Limited has addressed ASX concerns over delayed disclosure of PANCOSIL clinical trial results, confirming compliance with continuous disclosure obligations despite procedural oversights.
Ada Torres
Ada Torres
28 Oct 2025
Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.
Ada Torres
Ada Torres
28 Oct 2025
Anteris Technologies Global Corp. has had its trading suspension lifted following a key announcement about its capital raising plans, signaling renewed market activity.
Ada Torres
Ada Torres
28 Oct 2025
Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.
Ada Torres
Ada Torres
28 Oct 2025
Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.
Ada Torres
Ada Torres
28 Oct 2025
Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.
Ada Torres
Ada Torres
28 Oct 2025
Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.
Ada Torres
Ada Torres
28 Oct 2025
Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.
Ada Torres
Ada Torres
28 Oct 2025